首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2102983

全球發作性睡病流行病學分析與預測（2026 年）

Global Narcolepsy Epidemiology Analysis and Forecast, 2026

出版日期: 2026年07月03日 | 出版商:

Knowledge Sourcing Intelligence | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到 2026 年，全球嗜睡症患者人數將增加至 2035 年的 326 萬，年複合成長率為 1.8%。

發作性睡病是一種慢性神經系統睡眠障礙，其特徵為白天過度嗜睡、猝倒、睡眠癱瘓、入睡幻覺和夜間睡眠障礙。此病分為發作性睡病1型（NT1）、發作性睡病2型（NT2）及次發性性睡病。儘管發作性睡病被認為是一種罕見疾病，但隨著人們對該病認知的提高和診斷標準的規範化，在已開發國家和發展中國家的醫療體系中，發作性睡病的診斷率均有所上升。

市場促進因素

人們對睡眠障礙的認知不斷提高

醫生教育程度的提高、患者支持活動的加強以及公眾宣傳宣傳活動的擴大，正在提升人們對發作性睡病症狀的認知，並促進患者及早轉診至睡眠專科醫生。早期診斷有助於更準確地進行流行病學估算。

診斷技術的進步

多睡眠多項生理檢查、多階段睡眠潛伏期測試 (MSLT)、腦脊髓液下丘腦泌素測試和標準化診斷指南的廣泛應用，提高了整個醫療保健系統疾病識別的準確性。

睡眠醫學基礎設施的擴建

全球認證的睡眠檢查室和專業神經病學中心的數量不斷增加，這改善了診斷的可及性，並加強了流行病學報告系統。

改進流行病學監測

全國病患登記系統、電子健康記錄和基於人群的流行病學研究不斷加深我們對疾病盛行率、發生率和人口分佈的了解。

市場限制因素

延遲診斷

發作性睡病常被誤診為憂鬱症、癲癇、精神疾病或其他睡眠障礙，導致從症狀出現到最終確診之間有顯著的延遲。

診斷不足

症狀逐漸加重，由於專門的睡眠研究並非普遍可用，尤其是在中低收入國家，許多患者仍未被診斷出來。

缺乏流行病學數據

診斷方法、通報系統和醫療保健服務取得的區域差異，導致了各國盛行率估計值的差異。

流行病學調查結果

發作性睡病的全球流行病學情況可依疾病類型、診斷狀態、年齡層、性別和地區進行分類。

從疾病類型來看，發作性睡病包括1型（NT1）、2型（NT2）和次發性發作性睡病。 1型發作性睡病由於與猝倒和下丘腦泌素缺乏症有關，因此是臨床上最容易識別的類型，但2型發作性睡病患者的臨床症狀不太典型，因此常常診斷延遲。

分析內容包括總體盛行率、總體發病率、已確診病例和未確診患者，並按診斷狀態進行了細分。雖然已確診患者人數持續增加，但由於公眾意識薄弱和診斷延誤，仍有相當數量的患者未被確診。

從年齡層來看，流行病學分析涵蓋了兒童、青少年、成人和老年患者。雖然發病通常在兒童或青少年期，但由於症狀經常被忽視或誤診為其他疾病，診斷往往會延遲數年。

雖然流行病學研究通常報告稱，男性和女性的盛行率沒有顯著差異，但診斷和醫療保健方面的區域差異可能會影響報告的發病率。

流行病學趨勢

嗜睡症的流行病學情況仍在不斷變化。

主要趨勢如下：

確診患者人數增加。
提高醫生的認知有助於及早發現疾病。
睡眠醫學中心擴建。
標準化診斷標準的使用正在逐步推進。
加強流行病學監測系統和病患登記系統。
人們對2型嗜睡症的認知正在提高。
增加對罕見神經系統疾病研究的投入。

區域趨勢

由於北美擁有先進的睡眠醫學基礎設施、醫療保健專業人員的高度重視、診斷測試的廣泛普及以及積極主動的流行病學監測，因此北美是確診嗜睡症病例最多的地區之一。

在歐洲，透過專門的睡眠中心、神經病學領域的合作研究和標準化的診斷方案，維持著強力的流行病學監測，從而得出可靠的盛行率估計值。

在亞太地區，由於醫療基礎設施的擴建、睡眠檢查室的普及、公眾意識的提高以及神經學研究能力的增強，預計確診患者人數將顯著增加。日本、印度、韓國和澳洲等國家預計將對未來的流行病學成長做出重大貢獻。

在拉丁美洲、中東和非洲，隨著睡眠醫學服務和醫生教育的擴展，診斷系統正在不斷改進，但專家的數量有限，這意味著漏診仍然是一個重大挑戰。

流行病學情勢

在發作性睡病的流行病學研究中，電子健康記錄記錄、患者登記、縱向隊列研究和疾病建模正被擴大用於估算已確診和未確診患者的數量。這些數據為醫療保健規劃、臨床試驗招募、商業性機會評估以及未來治療方案的研發提供了支持。

前景

發作性睡病流行病學的未來發展將受益於診斷技術的進步、醫生認知水平的提高、流行病學監測的改進以及標準化診斷標準的廣泛應用。預計到2035年，數位健康工具、人工智慧（AI）輔助診斷和生物標記研究的日益普及將提高疾病檢測的準確性並減少診斷延遲。

結論

根據《全球發作性睡病流行病學分析》，預計到2035年，在公眾意識提高、診斷能力增強和睡眠醫學基礎設施擴充的推動下，發作性睡病確診患者人數將穩步成長。儘管發作性睡病仍然是一種罕見的神經系統疾病，但流行病學監測和診斷準確性的持續進步有望提高疾病識別率，支持臨床研究，並加強全球醫療保健規劃。

本報告的主要益處

對全球嗜睡症流行病學狀況的全面評估。
對盛行率、發生率、確診病例數和人口趨勢進行詳細分析。
依疾病類型、年齡、性別和地區評估疾病負擔。
為醫療規劃、臨床試驗設計和商業策略提供支援的洞察。
這將成為製藥公司、生技公司、醫療保健提供者、研究人員、政策制定者和投資者的寶貴資訊來源。

公司對我們報告的使用

患者群體預測、流行病學建模、臨床試驗規劃、醫療資源分配、商業性機會評估、投資分析、市場進入規劃和長期策略決策。

調查範圍

歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
對全球發作性睡病流行病學進行全面分析，並依疾病類型、診斷狀態、年齡層、性別和地區進行細分。
評估盛行率、發生率、確診病例數、人口分佈、疾病負擔和流行病學趨勢。
對特定國家的流行病學、特定年齡和性別的疾病模式、預測模型和區域流行病學差異進行評估。
對 1 型發作性睡病 (NT1)、2 型發作性睡病 (NT2)、次發性發作性睡病、已確診和未確診患者群體以及到 2035 年的未來流行病學趨勢進行分析。

Narcolepsy is a chronic neurological sleep disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations, and disrupted nighttime sleep. The disease is classified into Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and secondary narcolepsy. Although considered a rare disease, improvements in disease recognition and standardized diagnostic criteria are leading to increased diagnosis across both developed and emerging healthcare systems.

Market Drivers

Growing Awareness of Sleep Disorders

Increasing physician education, patient advocacy initiatives, and public awareness campaigns are improving recognition of narcolepsy symptoms and encouraging earlier referral to sleep specialists. Earlier diagnosis supports more accurate epidemiological estimates.

Advances in Diagnostic Technologies

Greater availability of polysomnography, multiple sleep latency testing (MSLT), cerebrospinal fluid hypocretin testing, and standardized diagnostic guidelines has improved disease identification across healthcare systems.

Expansion of Sleep Medicine Infrastructure

The increasing number of accredited sleep laboratories and specialized neurological centers worldwide is improving access to diagnosis and strengthening epidemiological reporting.

Improved Epidemiological Surveillance

National patient registries, electronic health records, and population-based epidemiological studies continue to enhance understanding of disease prevalence, incidence, and demographic distribution.

Market Restraints

Delayed Diagnosis

Narcolepsy is frequently misdiagnosed as depression, epilepsy, psychiatric illness, or other sleep disorders, resulting in significant delays between symptom onset and confirmed diagnosis.

Underdiagnosis

Many patients remain undiagnosed because symptoms develop gradually and specialized sleep testing is not universally available, particularly in low- and middle-income countries.

Limited Epidemiological Data

Regional differences in diagnostic practices, reporting systems, and healthcare access contribute to variability in prevalence estimates between countries.

Epidemiology Insights

The global narcolepsy epidemiology landscape can be segmented by disease type, diagnosis status, age group, gender, and geography.

By disease type, the epidemiology includes Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and secondary narcolepsy. Type 1 remains the most clinically recognized form because of its association with cataplexy and hypocretin deficiency, while Type 2 patients frequently experience delayed diagnosis because of less distinctive clinical presentation.

By diagnosis status, the analysis includes total prevalence, total incidence, diagnosed cases, and undiagnosed patients. Although diagnosed patient numbers continue increasing, a substantial proportion of patients remain undiagnosed because of limited awareness and diagnostic delays.

By age group, epidemiological analysis covers children, adolescents, adults, and elderly patients. Disease onset commonly occurs during childhood or adolescence, although diagnosis often takes place years later because symptoms are frequently overlooked or attributed to other conditions.

By gender, epidemiological studies generally report relatively similar prevalence between males and females, although regional differences in diagnosis and healthcare access may influence reported incidence.

Epidemiological Trends

The narcolepsy epidemiology landscape continues to evolve.

Key trends include:

Increasing diagnosed patient population.
Earlier recognition through improved physician awareness.
Expansion of sleep medicine centers.
Greater use of standardized diagnostic criteria.
Improved epidemiological surveillance and patient registries.
Growing recognition of Narcolepsy Type 2.
Increasing investment in rare neurological disease research.

Regional Insights

North America represents one of the largest diagnosed narcolepsy populations because of advanced sleep medicine infrastructure, high awareness among healthcare professionals, widespread availability of diagnostic testing, and active epidemiological surveillance.

Europe maintains strong epidemiological monitoring through specialized sleep centers, collaborative neurological research, and standardized diagnostic protocols, supporting reliable prevalence estimates.

Asia-Pacific is expected to experience significant growth in diagnosed patient populations owing to expanding healthcare infrastructure, improving access to sleep laboratories, increasing awareness, and stronger neurological research capabilities. Countries including Japan, India, South Korea, and Australia are expected to contribute substantially to future epidemiological growth.

Latin America and the Middle East & Africa continue improving diagnosis through expanding sleep medicine services and physician education, although underdiagnosis remains a significant challenge because of limited specialist availability.

Epidemiological Landscape

The epidemiological landscape for narcolepsy increasingly incorporates electronic health records, patient registries, longitudinal cohort studies, and disease modeling to estimate both diagnosed and undiagnosed populations. These data support healthcare planning, clinical trial recruitment, commercial opportunity assessment, and future therapeutic development.

Future Outlook

The future of narcolepsy epidemiology will be supported by advances in diagnostic technologies, greater physician awareness, improved epidemiological surveillance, and broader implementation of standardized diagnostic criteria. Increasing use of digital health tools, artificial intelligence-assisted diagnostics, and biomarker research is expected to improve disease detection while reducing diagnostic delays through 2035.

Conclusion

The Global Narcolepsy Epidemiology Analysis indicates steady growth in the diagnosed narcolepsy population through 2035, driven by increasing awareness, improved diagnostic capabilities, and expanding sleep medicine infrastructure. Although narcolepsy remains a rare neurological disorder, continued advances in epidemiological surveillance and diagnostic accuracy are expected to improve disease identification, support clinical research, and strengthen healthcare planning worldwide.

Key Benefits of this Report

Comprehensive assessment of the global narcolepsy epidemiological landscape.
Detailed analysis of prevalence, incidence, diagnosed cases, and demographic trends.
Evaluation of disease burden by type, age, gender, and geography.
Insights supporting healthcare planning, clinical trial design, and commercial strategy.
Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, policymakers, and investors.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological modeling, clinical trial planning, healthcare resource allocation, commercial opportunity assessment, investment analysis, market access planning, and long-term strategic decision-making.

Report Coverage

Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
Comprehensive analysis of global narcolepsy epidemiology by disease type, diagnosis status, age group, gender, and geography
Evaluation of prevalence, incidence, diagnosed patient population, demographic distribution, disease burden, and epidemiological trends
Assessment of country-level epidemiology, age-specific and gender-specific disease patterns, forecast models, and regional epidemiological variations
Analysis of Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), secondary narcolepsy, diagnosed and undiagnosed populations, and future epidemiological trends through 2035.

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Key Findings
1.3 Epidemiology Overview
1.4 Disease Burden Highlights
1.5 Diagnosed Population Trends
1.6 Regional Epidemiology Insights
1.7 Future Outlook (2025-2045)

2. Narcolepsy Disease Overview

2.1 Introduction to Narcolepsy
2.2 Disease Classification
- 2.2.1 Narcolepsy Type 1 (NT1)
- 2.2.2 Narcolepsy Type 2 (NT2)
- 2.2.3 Secondary Narcolepsy
2.3 Disease Pathophysiology
2.4 Hypocretin/Orexin Deficiency Mechanism
2.5 Genetic Factors
2.6 Autoimmune Associations
2.7 Clinical Manifestations
- 2.7.1 Excessive Daytime Sleepiness
- 2.7.2 Cataplexy
- 2.7.3 Sleep Paralysis
- 2.7.4 Hypnagogic and Hypnopompic Hallucinations
- 2.7.5 Disturbed Nocturnal Sleep
2.8 Disease Burden and Quality of Life Impact
2.9 Diagnosis and Diagnostic Challenges
2.10 Unmet Needs in Disease Recognition

3. Epidemiology Methodology

3.1 Study Objectives
3.2 Epidemiology Forecast Methodology
3.3 Data Sources and Assumptions
3.4 Disease Modeling Framework
3.5 Patient Population Estimation Methodology
3.6 Forecasting Approach (2025-2045)
3.7 Data Validation and Triangulation

4. Global Narcolepsy Epidemiology Overview

4.1 Total Prevalent Cases
4.2 Total Incident Cases
4.3 Diagnosed Prevalent Cases
4.4 Diagnosed Incident Cases
4.5 Treatable Patient Population
4.6 Disease Awareness Trends
4.7 Diagnostic Rate Trends
4.8 Epidemiology Forecast Analysis (2025-2045)

5. Epidemiology Segmentation by Disease Type

5.1 Narcolepsy Type 1 (NT1)
- 5.1.1 Prevalence
- 5.1.2 Incidence
- 5.1.3 Diagnosed Cases
- 5.1.4 Forecast Analysis
5.2 Narcolepsy Type 2 (NT2)
- 5.2.1 Prevalence
- 5.2.2 Incidence
- 5.2.3 Diagnosed Cases
- 5.2.4 Forecast Analysis
5.3 Secondary Narcolepsy
- 5.3.1 Prevalence
- 5.3.2 Incidence
- 5.3.3 Diagnosed Cases
- 5.3.4 Forecast Analysis

6. Epidemiology Segmentation by Age Group

6.1 Pediatric Population (<18 Years)
- 6.1.1 Prevalence
- 6.1.2 Incidence
- 6.1.3 Diagnosed Cases
- 6.1.4 Forecast Analysis
6.2 Adult Population (18-64 Years)
- 6.2.1 Prevalence
- 6.2.2 Incidence
- 6.2.3 Diagnosed Cases
- 6.2.4 Forecast Analysis
6.3 Elderly Population (?65 Years)
- 6.3.1 Prevalence
- 6.3.2 Incidence
- 6.3.3 Diagnosed Cases
- 6.3.4 Forecast Analysis

7. Epidemiology Segmentation by Gender

7.1 Male Population
- 7.1.1 Prevalence
- 7.1.2 Incidence
- 7.1.3 Diagnosed Cases
- 7.1.4 Forecast Analysis
7.2 Female Population
- 7.2.1 Prevalence
- 7.2.2 Incidence
- 7.2.3 Diagnosed Cases
- 7.2.4 Forecast Analysis

8. Epidemiology Segmentation by Symptom Profile

8.1 Narcolepsy with Cataplexy
- 8.1.1 Prevalence
- 8.1.2 Incidence
- 8.1.3 Diagnosed Cases
- 8.1.4 Forecast Analysis
8.2 Narcolepsy without Cataplexy
- 8.2.1 Prevalence
- 8.2.2 Incidence
- 8.2.3 Diagnosed Cases
- 8.2.4 Forecast Analysis

9. Diagnosis and Patient Journey Analysis

9.1 Disease Awareness Assessment
9.2 Symptom Recognition Trends
9.3 Time to Diagnosis Analysis
9.4 Misdiagnosis Assessment
9.5 Diagnostic Testing Landscape
9.6 Specialist Referral Pathways
9.7 Diagnosed versus Undiagnosed Population
9.8 Future Diagnostic Trends

10. Geographical Analysis

10.1 North America
- 10.1.1 Total Prevalence
- 10.1.2 Total Incidence
- 10.1.3 Diagnosed Cases
- 10.1.4 Disease Type Distribution
- 10.1.5 Age-Specific Epidemiology
- 10.1.6 Gender-Specific Epidemiology
- 10.1.7 Forecast Analysis
10.2 Europe
- 10.2.1 Total Prevalence
- 10.2.2 Total Incidence
- 10.2.3 Diagnosed Cases
- 10.2.4 Disease Type Distribution
- 10.2.5 Age-Specific Epidemiology
- 10.2.6 Gender-Specific Epidemiology
- 10.2.7 Forecast Analysis
10.3 Asia-Pacific
- 10.3.1 Total Prevalence
- 10.3.2 Total Incidence
- 10.3.3 Diagnosed Cases
- 10.3.4 Disease Type Distribution
- 10.3.5 Age-Specific Epidemiology
- 10.3.6 Gender-Specific Epidemiology
- 10.3.7 Forecast Analysis
10.4 Latin America
- 10.4.1 Total Prevalence
- 10.4.2 Total Incidence
- 10.4.3 Diagnosed Cases
- 10.4.4 Disease Type Distribution
- 10.4.5 Age-Specific Epidemiology
- 10.4.6 Gender-Specific Epidemiology
- 10.4.7 Forecast Analysis
10.5 Middle East & Africa
- 10.5.1 Total Prevalence
- 10.5.2 Total Incidence
- 10.5.3 Diagnosed Cases
- 10.5.4 Disease Type Distribution
- 10.5.5 Age-Specific Epidemiology
- 10.5.6 Gender-Specific Epidemiology
- 10.5.7 Forecast Analysis

11. Key Countries Analysis

11.1 United States
- 11.1.1 Total Prevalence
- 11.1.2 Total Incidence
- 11.1.3 Diagnosed Cases
- 11.1.4 Disease Type Distribution
- 11.1.5 Age-Specific Epidemiology
- 11.1.6 Gender-Specific Epidemiology
- 11.1.7 Forecast Analysis
11.2 Canada
- 11.2.1 Total Prevalence
- 11.2.2 Total Incidence
- 11.2.3 Diagnosed Cases
- 11.2.4 Disease Type Distribution
- 11.2.5 Age-Specific Epidemiology
- 11.2.6 Gender-Specific Epidemiology
- 11.2.7 Forecast Analysis
11.3 Germany
- 11.3.1 Total Prevalence
- 11.3.2 Total Incidence
- 11.3.3 Diagnosed Cases
- 11.3.4 Disease Type Distribution
- 11.3.5 Age-Specific Epidemiology
- 11.3.6 Gender-Specific Epidemiology
- 11.3.7 Forecast Analysis
11.4 United Kingdom
- 11.4.1 Total Prevalence
- 11.4.2 Total Incidence
- 11.4.3 Diagnosed Cases
- 11.4.4 Disease Type Distribution
- 11.4.5 Age-Specific Epidemiology
- 11.4.6 Gender-Specific Epidemiology
- 11.4.7 Forecast Analysis
11.5 France
- 11.5.1 Total Prevalence
- 11.5.2 Total Incidence
- 11.5.3 Diagnosed Cases
- 11.5.4 Disease Type Distribution
- 11.5.5 Age-Specific Epidemiology
- 11.5.6 Gender-Specific Epidemiology
- 11.5.7 Forecast Analysis
11.6 Italy
- 11.6.1 Total Prevalence
- 11.6.2 Total Incidence
- 11.6.3 Diagnosed Cases
- 11.6.4 Disease Type Distribution
- 11.6.5 Age-Specific Epidemiology
- 11.6.6 Gender-Specific Epidemiology
- 11.6.7 Forecast Analysis
11.7 Spain
- 11.7.1 Total Prevalence
- 11.7.2 Total Incidence
- 11.7.3 Diagnosed Cases
- 11.7.4 Disease Type Distribution
- 11.7.5 Age-Specific Epidemiology
- 11.7.6 Gender-Specific Epidemiology
- 11.7.7 Forecast Analysis
11.8 China
- 11.8.1 Total Prevalence
- 11.8.2 Total Incidence
- 11.8.3 Diagnosed Cases
- 11.8.4 Disease Type Distribution
- 11.8.5 Age-Specific Epidemiology
- 11.8.6 Gender-Specific Epidemiology
- 11.8.7 Forecast Analysis
11.9 Japan
- 11.9.1 Total Prevalence
- 11.9.2 Total Incidence
- 11.9.3 Diagnosed Cases
- 11.9.4 Disease Type Distribution
- 11.9.5 Age-Specific Epidemiology
- 11.9.6 Gender-Specific Epidemiology
- 11.9.7 Forecast Analysis
11.10 India
- 11.10.1 Total Prevalence
- 11.10.2 Total Incidence
- 11.10.3 Diagnosed Cases
- 11.10.4 Disease Type Distribution
- 11.10.5 Age-Specific Epidemiology
- 11.10.6 Gender-Specific Epidemiology
- 11.10.7 Forecast Analysis
11.11 South Korea
- 11.11.1 Total Prevalence
- 11.11.2 Total Incidence
- 11.11.3 Diagnosed Cases
- 11.11.4 Disease Type Distribution
- 11.11.5 Age-Specific Epidemiology
- 11.11.6 Gender-Specific Epidemiology
- 11.11.7 Forecast Analysis
11.12 Australia
- 11.12.1 Total Prevalence
- 11.12.2 Total Incidence
- 11.12.3 Diagnosed Cases
- 11.12.4 Disease Type Distribution
- 11.12.5 Age-Specific Epidemiology
- 11.12.6 Gender-Specific Epidemiology
- 11.12.7 Forecast Analysis

12. Epidemiology Data Tables and Forecast Models

12.1 Global Epidemiology Forecast Tables (2025-2045)
12.2 Regional Epidemiology Forecast Tables
12.3 Country-Level Epidemiology Forecast Tables
12.4 Disease Type Forecast Models
12.5 Age-Specific Forecast Models
12.6 Gender-Specific Forecast Models
12.7 Diagnosed Population Forecast Models
12.8 Sensitivity Analysis

13. Company Profiles

13.1 Jazz Pharmaceuticals plc
- 13.1.1 Overview
- 13.1.2 Financials
- 13.1.3 Narcolepsy Portfolio Overview
- 13.1.4 Epidemiology-Based Market Strategy
- 13.1.5 Key Narcolepsy Products
- 13.1.6 Commercial Positioning
- 13.1.7 Recent Developments
13.2 Harmony Biosciences Holdings, Inc.
- 13.2.1 Overview
- 13.2.2 Financials
- 13.2.3 Narcolepsy Portfolio Overview
- 13.2.4 Epidemiology-Based Market Strategy
- 13.2.5 Key Narcolepsy Products
- 13.2.6 Commercial Positioning
- 13.2.7 Recent Developments
13.3 Avadel Pharmaceuticals plc
- 13.3.1 Overview
- 13.3.2 Financials
- 13.3.3 Narcolepsy Portfolio Overview
- 13.3.4 Epidemiology-Based Market Strategy
- 13.3.5 Key Narcolepsy Products
- 13.3.6 Commercial Positioning
- 13.3.7 Recent Developments
13.4 Takeda Pharmaceutical Company Limited
- 13.4.1 Overview
- 13.4.2 Financials
- 13.4.3 Narcolepsy Portfolio Overview
- 13.4.4 Epidemiology-Based Market Strategy
- 13.4.5 Key Narcolepsy Products
- 13.4.6 Commercial Positioning
- 13.4.7 Recent Developments
13.5 Axsome Therapeutics, Inc.
- 13.5.1 Overview
- 13.5.2 Financials
- 13.5.3 Narcolepsy Portfolio Overview
- 13.5.4 Epidemiology-Based Market Strategy
- 13.5.5 Key Narcolepsy Products
- 13.5.6 Commercial Positioning
- 13.5.7 Recent Developments
13.6 Centessa Pharmaceuticals plc
- 13.6.1 Overview
- 13.6.2 Financials
- 13.6.3 Narcolepsy Portfolio Overview
- 13.6.4 Epidemiology-Based Market Strategy
- 13.6.5 Key Narcolepsy Products
- 13.6.6 Commercial Positioning
- 13.6.7 Recent Developments
13.7 NLS Pharmaceutics Ltd.
- 13.7.1 Overview
- 13.7.2 Financials
- 13.7.3 Narcolepsy Portfolio Overview
- 13.7.4 Epidemiology-Based Market Strategy
- 13.7.5 Key Narcolepsy Products
- 13.7.6 Commercial Positioning
- 13.7.7 Recent Developments
13.8 Alkermes plc
- 13.8.1 Overview
- 13.8.2 Financials
- 13.8.3 Narcolepsy Portfolio Overview
- 13.8.4 Epidemiology-Based Market Strategy
- 13.8.5 Key Narcolepsy Products
- 13.8.6 Commercial Positioning
- 13.8.7 Recent Developments
13.9 Idorsia Ltd.
- 13.9.1 Overview
- 13.9.2 Financials
- 13.9.3 Narcolepsy Portfolio Overview
- 13.9.4 Epidemiology-Based Market Strategy
- 13.9.5 Key Narcolepsy Products
- 13.9.6 Commercial Positioning
- 13.9.7 Recent Developments
13.10 Aardvark Therapeutics, Inc.
- 13.10.1 Overview
- 13.10.2 Financials
- 13.10.3 Narcolepsy Portfolio Overview
- 13.10.4 Epidemiology-Based Market Strategy
- 13.10.5 Key Narcolepsy Products
- 13.10.6 Commercial Positioning
- 13.10.7 Recent Developments